<DOC>
	<DOCNO>NCT01700114</DOCNO>
	<brief_summary>The purpose study collect data describe real-world use safety effectiveness MelaFind® post-approval clinical setting .</brief_summary>
	<brief_title>Post-Approval Study MelaFind</brief_title>
	<detailed_description>The primary objective study test hypothesis , among eligible evaluable lesion central histological reference standard status melanoma high-grade lesion , relative sensitivity ρ compare enrol dermatologist MelaFind use enrol dermatologist MelaFind available great 110 % . This represent clinically meaningful increase sensitivity . The secondary objective study evaluate real-world use safety effectiveness MelaFind clinical setting .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>The lesion pigment ( i.e. , melanin , keratin , blood ) Clinical management lesion examine dermatologist either biopsy lesion toto , 3month followup lesion The diameter pigment area 2 22 millimeter The lesion accessible MelaFind handheld image device The patient , legally authorize representative , consent participate study sign Informed Consent Form The patient know allergy isopropyl alcohol The lesion previously biopsied , excise , traumatize The skin intact ( e.g. , open sore , ulcer , bleed ) The lesion within 1 cm eye The lesion mucosal surface ( e.g. , lip , genitals ) The lesion palmar hand The lesion plantar foot The lesion nail The lesion locate area visible scar The lesion contain foreign matter ( e.g. , tattoo , splinter , marker )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Pigmented Skin Lesions</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>MelaFind</keyword>
</DOC>